ZA200802897B - New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease - Google Patents
New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's DiseaseInfo
- Publication number
- ZA200802897B ZA200802897B ZA200802897A ZA200802897A ZA200802897B ZA 200802897 B ZA200802897 B ZA 200802897B ZA 200802897 A ZA200802897 A ZA 200802897A ZA 200802897 A ZA200802897 A ZA 200802897A ZA 200802897 B ZA200802897 B ZA 200802897B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrimidine derivatives
- alzheimer
- medicament
- therapy
- disease
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 2
- 150000003230 pyrimidines Chemical class 0.000 title 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0502174 | 2005-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200802897B true ZA200802897B (en) | 2008-12-31 |
Family
ID=37906403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200802897A ZA200802897B (en) | 2005-10-03 | 2008-04-02 | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20090105252A1 (https=) |
| EP (1) | EP1945628A4 (https=) |
| JP (1) | JP2009513575A (https=) |
| KR (1) | KR20080059423A (https=) |
| CN (1) | CN101326179A (https=) |
| AR (1) | AR058073A1 (https=) |
| AU (2) | AU2006297890B2 (https=) |
| BR (1) | BRPI0616658A2 (https=) |
| CA (1) | CA2624875A1 (https=) |
| EC (1) | ECSP088405A (https=) |
| IL (1) | IL190150A0 (https=) |
| NO (1) | NO20082067L (https=) |
| NZ (2) | NZ591316A (https=) |
| RU (2) | RU2433128C2 (https=) |
| SG (1) | SG166125A1 (https=) |
| TW (1) | TW200800957A (https=) |
| UA (1) | UA92181C2 (https=) |
| UY (1) | UY29827A1 (https=) |
| WO (1) | WO2007040440A1 (https=) |
| ZA (1) | ZA200802897B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| WO2009017455A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
| US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
| CA2729909A1 (en) * | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| WO2010009166A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Oxindolyl inhibitor compounds |
| CN102123987A (zh) | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物 |
| US8536185B2 (en) * | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| US20120077813A1 (en) * | 2009-04-15 | 2012-03-29 | Astrazeneca Ab | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease |
| GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
| KR20120031170A (ko) | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| US8283357B2 (en) | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
| WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| EP3741375A1 (en) | 2014-07-17 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| KR102342803B1 (ko) * | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
| AU2021243887A1 (en) * | 2020-03-23 | 2022-11-03 | Korea Research Institute Of Chemical Technology | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same |
| TW202227401A (zh) * | 2020-10-23 | 2022-07-16 | 大陸商重慶兩江藥物研發中心有限公司 | 用於持續釋放治療劑的前藥及其用途 |
| EP4238975A4 (en) * | 2020-10-29 | 2024-06-12 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| WO2022232259A1 (en) * | 2021-04-28 | 2022-11-03 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3530710A1 (de) | 1985-08-28 | 1987-03-05 | Hoechst Ag | Verfahren zur herstellung von halogenphenyl-oxethyl-sulfiden und deren oxidationsprodukten |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| ES2316546T3 (es) * | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
| SE0100569D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| HUP0402106A3 (en) * | 2001-11-01 | 2009-07-28 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7442697B2 (en) * | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| JP2006518381A (ja) * | 2003-02-07 | 2006-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール |
| US7456190B2 (en) * | 2003-03-13 | 2008-11-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| JP2007500178A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| US7132651B2 (en) | 2004-04-23 | 2006-11-07 | Framatome Anp, Inc. | In-situ BWR and PWR CRUD flake analysis method and tool |
| JP4278172B2 (ja) * | 2005-07-30 | 2009-06-10 | アストラゼネカ アクチボラグ | 増殖性疾患の治療において使用するためのイミダゾリル−ピリミジン化合物 |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| US20120077813A1 (en) * | 2009-04-15 | 2012-03-29 | Astrazeneca Ab | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease |
-
2006
- 2006-09-29 UY UY29827A patent/UY29827A1/es not_active Application Discontinuation
- 2006-09-29 AR ARP060104310A patent/AR058073A1/es not_active Application Discontinuation
- 2006-10-02 NZ NZ591316A patent/NZ591316A/en not_active IP Right Cessation
- 2006-10-02 WO PCT/SE2006/001116 patent/WO2007040440A1/en not_active Ceased
- 2006-10-02 UA UAA200802783A patent/UA92181C2/ru unknown
- 2006-10-02 US US12/089,008 patent/US20090105252A1/en not_active Abandoned
- 2006-10-02 CN CNA2006800454648A patent/CN101326179A/zh active Pending
- 2006-10-02 RU RU2008110910/04A patent/RU2433128C2/ru not_active IP Right Cessation
- 2006-10-02 KR KR1020087010755A patent/KR20080059423A/ko not_active Ceased
- 2006-10-02 BR BRPI0616658-0A patent/BRPI0616658A2/pt not_active IP Right Cessation
- 2006-10-02 JP JP2008534486A patent/JP2009513575A/ja active Pending
- 2006-10-02 SG SG201007265-0A patent/SG166125A1/en unknown
- 2006-10-02 EP EP06799716A patent/EP1945628A4/en not_active Withdrawn
- 2006-10-02 NZ NZ566804A patent/NZ566804A/en not_active IP Right Cessation
- 2006-10-02 CA CA002624875A patent/CA2624875A1/en not_active Abandoned
- 2006-10-02 AU AU2006297890A patent/AU2006297890B2/en not_active Ceased
- 2006-10-03 TW TW095136796A patent/TW200800957A/zh unknown
-
2008
- 2008-03-13 IL IL190150A patent/IL190150A0/en not_active IP Right Cessation
- 2008-04-02 ZA ZA200802897A patent/ZA200802897B/xx unknown
- 2008-04-28 EC EC2008008405A patent/ECSP088405A/es unknown
- 2008-04-30 NO NO20082067A patent/NO20082067L/no not_active Application Discontinuation
-
2011
- 2011-03-03 AU AU2011200948A patent/AU2011200948A1/en not_active Abandoned
- 2011-04-20 RU RU2011115406/04A patent/RU2011115406A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006297890A1 (en) | 2007-04-12 |
| NZ591316A (en) | 2012-06-29 |
| SG166125A1 (en) | 2010-11-29 |
| CA2624875A1 (en) | 2007-04-12 |
| UA92181C2 (ru) | 2010-10-11 |
| EP1945628A1 (en) | 2008-07-23 |
| AU2011200948A1 (en) | 2011-03-24 |
| RU2011115406A (ru) | 2012-10-27 |
| BRPI0616658A2 (pt) | 2011-06-28 |
| JP2009513575A (ja) | 2009-04-02 |
| IL190150A0 (en) | 2008-08-07 |
| EP1945628A4 (en) | 2010-06-02 |
| RU2008110910A (ru) | 2009-11-10 |
| RU2433128C2 (ru) | 2011-11-10 |
| AU2006297890B2 (en) | 2011-04-28 |
| ECSP088405A (es) | 2008-05-30 |
| KR20080059423A (ko) | 2008-06-27 |
| AR058073A1 (es) | 2008-01-23 |
| WO2007040440A1 (en) | 2007-04-12 |
| NO20082067L (no) | 2008-07-02 |
| UY29827A1 (es) | 2007-05-31 |
| US20090105252A1 (en) | 2009-04-23 |
| CN101326179A (zh) | 2008-12-17 |
| TW200800957A (en) | 2008-01-01 |
| NZ566804A (en) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190150A0 (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease | |
| EP1979324A4 (en) | IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE DISORDER, MORBUS ALZHEIMER, NEURODEGENERATION AND DEMENTIA. | |
| TWI340640B (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
| ES2414872T8 (es) | Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente | |
| ZA200703601B (en) | Medicaments for the treatment or prevention of fibriotic diseases | |
| IL191311A (en) | Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury | |
| EP2091566A4 (en) | COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES | |
| PL1656372T3 (pl) | Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym | |
| WO2007012061A3 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
| IL190284A (en) | Use of milenzipran, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia | |
| PT2083837E (pt) | Utilização terapêutica de pelo menos uma neurotoxina botulínica no tratamento da dor induzida por, pelo menos, um agente anti-cancerígeno | |
| EP1940373B8 (en) | 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease | |
| TWI372056B (en) | Novel medicament combinations for the treatment of respiratory diseases | |
| IL185300A0 (en) | New pharmaceutical compositions useful in the treatment of parkinson's disease | |
| IL177787A0 (en) | 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
| GB0410399D0 (en) | The treatment of respiratory disease | |
| IL178815A0 (en) | The treatment of respiratory disease | |
| PL1868623T3 (pl) | Zastosowanie LGG w wytwarzaniu leku do zapobiegania lub leczenia alergii oddechowych | |
| PL1670482T5 (pl) | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego | |
| IL186022A0 (en) | Dermatological compositions and salts for the treatment of dermatological diseases | |
| AU2003238046A1 (en) | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease | |
| LT1807156T (lt) | Naujos farmacinės kompozicijos, naudingos nemigos gydyme | |
| HK1120037A (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease | |
| HK1119947A (zh) | 嘧啶衍生物在制造用於防止和/或治疗阿兹海默氏症的药物中的用途 | |
| GB0425633D0 (en) | Topical formulations for use in the treatment or prevention of dermatological conditions |